Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results

By sjmartinez • January 31, 2024

Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs GS, Kremyanskaya M, Winton EF, O'Connell C, Goel S, Oh ST, Schiller GJ, McCloskey J, Palmer JM, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver NG. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results. Blood Adv. 2024 Jan 30:bloodadvances.2023011620. doi: 10.1182/bloodadvances.2023011620. Epub ahead of print. PMID: 38290135.

Tags: Hematology/Oncology, Publications

Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden

Williamson TJ, Garon EB, Irwin MR, Choi AK, Goldman JW, Stanton AL. Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and[...]

Mutation of SIVA, a candidate metastasis gene identified from clonally related bilateral breast cancers, promotes breast cancer cell spread in vitro and in vivo

Vermehren-Schmaedick A, Peto M, Wagoner W, Chiotti KE, Ramsey E, Wang X, Rakshe S, Minnier J, Sears R, Spellman P, Luoh SW. Mutation of SIVA,[...]

A tale of two marital stressors: Comparing proinflammatory responses to partner distress and marital conflict

Wilson SJ, Syed SU, Yang IS, Cole SW. A tale of two marital stressors: Comparing proinflammatory responses to partner distress and marital conflict. Brain Behav[...]